BNP PARIBAS ASSET MANAGEMENT Holding S.A. Raises Position in Royalty Pharma plc (NASDAQ:RPRX)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 58.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 634,501 shares of the biopharmaceutical company’s stock after acquiring an additional 234,991 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.11% of Royalty Pharma worth $17,950,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board raised its stake in shares of Royalty Pharma by 5.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 923,639 shares of the biopharmaceutical company’s stock worth $28,051,000 after buying an additional 45,839 shares in the last quarter. BOKF NA lifted its holdings in Royalty Pharma by 18.4% in the first quarter. BOKF NA now owns 18,280 shares of the biopharmaceutical company’s stock valued at $547,000 after acquiring an additional 2,844 shares during the period. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Royalty Pharma during the 1st quarter worth $487,000. California State Teachers Retirement System boosted its position in shares of Royalty Pharma by 2.1% during the 1st quarter. California State Teachers Retirement System now owns 649,055 shares of the biopharmaceutical company’s stock worth $19,712,000 after purchasing an additional 13,533 shares in the last quarter. Finally, Tidal Investments LLC grew its stake in shares of Royalty Pharma by 28.2% during the 1st quarter. Tidal Investments LLC now owns 90,149 shares of the biopharmaceutical company’s stock worth $2,740,000 after purchasing an additional 19,834 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Trading Up 0.1 %

Shares of RPRX opened at $26.43 on Friday. Royalty Pharma plc has a 1-year low of $25.10 and a 1-year high of $31.66. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The firm has a 50 day simple moving average of $27.30 and a 200-day simple moving average of $27.39. The stock has a market cap of $15.57 billion, a price-to-earnings ratio of 13.69, a price-to-earnings-growth ratio of 4.59 and a beta of 0.47.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $0.21 dividend. The ex-dividend date is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.18%. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Wall Street Analyst Weigh In

Several analysts recently commented on RPRX shares. The Goldman Sachs Group raised their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Citigroup decreased their price target on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $41.67.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.